Compare WOLF & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOLF | BNTC |
|---|---|---|
| Founded | 1987 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 505.2M | 411.4M |
| IPO Year | 2025 | 2020 |
| Metric | WOLF | BNTC |
|---|---|---|
| Price | $17.01 | $11.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $12.75 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 1.3M | 177.5K |
| Earning Date | 05-07-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,385,982,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $0.39 | $9.85 |
| 52 Week High | $36.60 | $17.15 |
| Indicator | WOLF | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 45.44 | 49.32 |
| Support Level | $16.64 | $11.30 |
| Resistance Level | $22.59 | $13.06 |
| Average True Range (ATR) | 1.62 | 0.77 |
| MACD | -0.18 | 0.06 |
| Stochastic Oscillator | 22.06 | 41.02 |
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.